Fredun Pharmaceuticals Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 09, 2026

Key Highlights

The Latest Trading Price of Fredun Pharmaceuticals Ltd is ₹ 2374 as of 08 May 15:30 . The P/E Ratio of Fredun Pharmaceuticals Ltd changed from 16 on March 2025 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 41.5 on March 2025 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 years The Market Cap of Fredun Pharmaceuticals Ltd changed from ₹ 315.67 crore on March 2025 to ₹ 0 crore on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 43458 crore on March 2025 to ₹ 27019 crore on March 2024 . This represents a CAGR of -9.07% over 5 years The revenue of Fredun Pharmaceuticals Ltd for the Dec '25 is ₹ 160.92 crore as compare to the Sep '25 revenue of ₹ 145.29 crore. This represent the growth of 10.76% The revenue of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 3945 crore as compare to the Sep '25 revenue of ₹ 6247 crore. This represent the decline of -36.85% The ebitda of Fredun Pharmaceuticals Ltd for the Dec '25 is ₹ 26.34 crore as compare to the Sep '25 ebitda of ₹ 22.33 crore. This represent the growth of 17.96% The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 729.88 crore as compare to the Sep '25 ebitda of ₹ 1175 crore. This represent the decline of -37.89% The net profit of Fredun Pharmaceuticals Ltd changed from ₹ 13.74 crore to ₹ 10.48 crore over 5 quarters. This represents a CAGR of -19.48% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 403.23 crore over 7 quarters. This represents a CAGR of 10.19% The Dividend Payout of Fredun Pharmaceuticals Ltd changed from 13.9 % on March 2021 to 1.59 % on March 2025 . This represents a CAGR of -35.18% over 5 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 years .

About Fredun Pharmaceuticals Ltd

Incorporated in 1987 as a private limited company, Fredun Pharmaceuticals Limited (FPL) was converted into a public limited company in Mar.'94.
The Company was promoted by Nariman Medhora and Daulat N Medhora.
The promoters initially established D N Pharma, a proprietary firm, for the manufacture and export of pharmaceutical formulations.
Since 1993, D N Pharma's operations were phased out in order to switch over the business to FPL. The Company is well diversified in the business ranging from Formulations to Diagnostics to Consultancy.
The Company has an unique range of products, from niche formulations , anti-diabetics to the latest antiretroviral and anti - Hypertensive products.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

FAQs for the comparison of Fredun Pharmaceuticals Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Fredun Pharmaceuticals Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Fredun Pharmaceuticals Ltd is 1,309 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 66,722 Cr

What are the key factors driving the stock performance of Fredun Pharmaceuticals Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Fredun Pharmaceuticals Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Fredun Pharmaceuticals Ltd and Glenmark Pharmaceuticals Ltd?

As of May 9, 2026, the Fredun Pharmaceuticals Ltd stock price is INR ₹2374.95. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹2364.35.

How do dividend payouts of Fredun Pharmaceuticals Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Fredun Pharmaceuticals Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.